Recombinant antibodies are rapidly developing therapeutic agents; approximately 40 novel antibody molecules enter clinical trials each year, most of which are produced from Chinese hamster ovary (CHO) ...

Chinese hamster ovary (CHO) cells are by far the most commonly used mammalian expression system for recombinant expression of therapeutic proteins in the pharmaceutical industry. The development of ...

The use of recombinant thyroid-stimulating hormone (Thyrogen ®) should increase and replace thyroxine withdrawal in preparation for 131 I therapy. Treatment-enhancing regimes using lithium or ...

Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer ...